Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard M Stern

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Cancer Research|January 21, 2006
Oncogenic BRAF is required for tumor growth and maintenance in melanoma modelsKlaus P Hoeflich, Daniel C Gray, Michael T Eby, et al.
Molecular Cancer Research : MCR|April 18, 2009
Genetic alterations and oncogenic pathways associated with breast cancer subtypesXiaolan Hu, Howard M Stern, Lin Ge, et al.
Molecular Cancer Research : MCR|August 13, 2009
Oncogenic activating mutations are associated with local copy gainBarmak Modrek, Lin Ge, Ajay Pandita, et al.
American Journal of Hematology|August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 studySusan O'Brien, Manish Patel, Brad S Kahl, et al.
Genes & Development|January 11, 2007
A mutation in separase causes genome instability and increased susceptibility to epithelial cancerJennifer L Shepard, James F Amatruda, David Finkelstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
The Journal of Cell Biology|October 8, 2008
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agentsMichael Degtyarev, Ann De Mazière, Christine Orr, et al.
Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.
Science Signaling|August 27, 2011
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Signaling|June 16, 2011
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Cancer Research|January 21, 2006
Oncogenic BRAF is required for tumor growth and maintenance in melanoma modelsKlaus P Hoeflich, Daniel C Gray, Michael T Eby, et al.
Molecular Cancer Research : MCR|April 18, 2009
Genetic alterations and oncogenic pathways associated with breast cancer subtypesXiaolan Hu, Howard M Stern, Lin Ge, et al.
Molecular Cancer Research : MCR|August 13, 2009
Oncogenic activating mutations are associated with local copy gainBarmak Modrek, Lin Ge, Ajay Pandita, et al.
American Journal of Hematology|August 11, 2018
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 studySusan O'Brien, Manish Patel, Brad S Kahl, et al.
Genes & Development|January 11, 2007
A mutation in separase causes genome instability and increased susceptibility to epithelial cancerJennifer L Shepard, James F Amatruda, David Finkelstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
The Journal of Cell Biology|October 8, 2008
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agentsMichael Degtyarev, Ann De Mazière, Christine Orr, et al.
Breast Cancer Research and Treatment|February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Edith A Perez, Michael F Press, Amylou C Dueck, et al.
Science Signaling|August 27, 2011
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Signaling|June 16, 2011
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Pageof 4